Form 4: Ultragenyx CFO Howard Horn Executes Stock Sale

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn sold 4,653 shares of common stock on June 1, 2026.

Summary

• CFO Howard Horn sold 4,653 shares of Ultragenyx Pharmaceutical Inc. (RARE) common stock.
• The transaction was executed at a price of $23.77 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan.
• Following the transaction, the reporting person retains beneficial ownership of 105,689 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-arranged 10b5-1 plan, which is a routine administrative action for corporate officers.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, which typically indicates the sale is for personal financial planning rather than a reaction to non-public information.

Negatives

• The sale represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice among biotech executives to avoid potential insider trading concerns.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the executive's total holdings.

Key Dates

Keywords

Ultragenyx, RARE, Insider Trading, Form 4, CFO, Stock Sale